Song Dongjian, Yue Lifang, Zhang Junjie, Ma Shanshan, Zhao Wei, Guo Fei, Fan Yingzhong, Yang Heying, Liu Qiuliang, Zhang Da, Xia Ziqiang, Qin Pan, Jia Jia, Yue Ming, Yu Jiekai, Zheng Shu, Yang Fuquan, Wang Jiaxiang
a Department of Pediatric Surgery , First Affiliated Hospital, Zhengzhou University , Zhengzhou , PR China.
b Institute of Clinical Medicine, First Affiliated Hospital, Zhengzhou University , Zhengzhou , PR China.
Cancer Biol Ther. 2016 Jun 2;17(6):635-47. doi: 10.1080/15384047.2016.1156262. Epub 2016 Jun 3.
Women with triple-negative breast cancer (TNBC) have poor prognosis because of the aggressive nature of the tumor, delayed diagnosis and non-specific symptoms in the early stages. Identification of novel specific TNBC serum biomarkers for screening and therapeutic purposes therefore remains an urgent clinical requirement.We obtained serum samples from a total of 380 recruited individuals split into mining and testing sets, with the aim of screening for reliable protein biomarkers from TNBC and non-TNBC (NTNBC) sera. Samples were assessed using mass spectrometry, followed by receiver operating characteristic (ROC), survival and hazard function curve as well as multivariate Cox regression analyses to ascertain the potential of the protein constituents as diagnostic and prognostic biomarkers for TNBC.We identified upregulated apolipoprotein C-I (apoC-I) with a validated positive effect on TNBC tumorigenesis, with confirmation in an independent test set and minimization of systematic bias by pre-analytical parameters. The apoC-I protein had superior diagnostic ability in distinguishing between TNBC and NTNBC cases. Moreover, the protein presented a more robust potential prognostic factor for TNBC than NTNBC. The apoC-I protein identified in this study presents an effective novel diagnostic and prognostic biomarker for TNBC, indicating that measurement of the peak intensity at 7785 Da in serum samples could facilitate improved early detection and estimation of postoperative survival prognosis for TNBC.
三阴性乳腺癌(TNBC)女性患者预后较差,原因在于肿瘤的侵袭性、诊断延迟以及早期阶段的非特异性症状。因此,鉴定用于筛查和治疗目的的新型特异性TNBC血清生物标志物仍然是一项紧迫的临床需求。我们从总共380名招募个体中获取血清样本,分为挖掘集和测试集,旨在从TNBC和非TNBC(NTNBC)血清中筛选可靠的蛋白质生物标志物。使用质谱对样本进行评估,随后进行受试者工作特征(ROC)、生存和风险函数曲线以及多变量Cox回归分析,以确定蛋白质成分作为TNBC诊断和预后生物标志物的潜力。我们鉴定出载脂蛋白C-I(apoC-I)上调,对TNBC肿瘤发生具有验证的积极作用,在独立测试集中得到证实,并通过分析前参数将系统偏差降至最低。apoC-I蛋白在区分TNBC和NTNBC病例方面具有卓越的诊断能力。此外,该蛋白对TNBC而言是比NTNBC更强有力的潜在预后因素。本研究中鉴定出的apoC-I蛋白是一种有效的新型TNBC诊断和预后生物标志物,表明测量血清样本中7785 Da处的峰强度有助于改善TNBC的早期检测和术后生存预后评估。